Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer
Abstract Background The current precision medicine relies on biomarkers, which are mainly obtained through next-generation sequencing (NGS). However, this model failed to find effective drugs for most cancer patients. This study tried to combine liquid biopsy with functional drug tests using organoi...
Main Authors: | Huan Yang, Xing Xiao, Leli Zeng, Haiteng Zeng, Yueyuan Zheng, Jingshu Wang, Guanghua Li, Weigang Dai, Yulong He, Suihai Wang, Jianjun Peng, Wei Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-02-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12967-023-04675-6 |
Similar Items
-
The cfDNA in early cancer detection
by: Hussein Adil Abid, et al.
Published: (2024-01-01) -
Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
by: Yi-Ze Li, et al.
Published: (2023-02-01) -
Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
by: Jonathan Dao, et al.
Published: (2023-08-01) -
What fraction of cellular DNA turnover becomes cfDNA?
by: Ron Sender, et al.
Published: (2024-02-01) -
cfDNA Methylation Profiles and T-Cell Differentiation in Women with Endometrial Polyps
by: Xiao-Hong Li, et al.
Published: (2022-12-01)